Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical
company dedicated to the discovery, development, and
commercialization of TGF-beta superfamily therapeutics to treat
serious and rare diseases, today announced that a total of six
distinct abstracts on REBLOZYL® (luspatercept-aamt) will be
presented at the upcoming 2020 American Society of Clinical
Oncology 2020 (ASCO20) Virtual Scientific Program, held May 29-31,
and at the 25th Annual European Hematology Association (EHA25)
Virtual Congress, held June 11-21.
Poster Presentations at ASCO20 Virtual
Scientific Program
Title:
Longer-Term RBC Transfusion
Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients
(Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring
Sideroblasts (RS) - Abstract: #7518
Session:
Hematologic
Malignancies—Leukemia, Myelodysplastic Syndromes, and
Allotransplant
Title:
Clinical Benefit of
Luspatercept in Patients (Pts) With Lower-Risk MDS (LR-MDS) and
High Transfusion Burden in the Phase 3 MEDALIST Study -
Abstract: #7554
Session:
Hematologic
Malignancies—Leukemia, Myelodysplastic Syndromes, and
Allotransplant
Poster presentations and poster discussions will be available on
demand through the ASCO20 Virtual Scientific Program beginning on
May 29, 2020, at 8:00 a.m. EDT.
Presentations at EHA25 Virtual
Congress
Title:
Assessment of Response to
Luspatercept by β-Globin Genotype in Adult Patients With
β-Thalassemia in the BELIEVE Trial - Abstract: Oral presentation
S295
Title:
Assessment of Longer-Term
Efficacy and Safety in the Phase 3 BELIEVE Trial of Luspatercept to
Treat Anemia in Patients (Pts) with β-Thalassemia -
Abstract: e-Poster 1548
Title:
Assessment of Dose-Dependent
Response to Luspatercept in Patients (Pts) With Lower-Risk
Myelodysplastic Syndromes (LR-MDS) With Ring Sideroblasts in the
Phase 3 MEDALIST Trial - Abstract: e-Poster 812
Title:
Effects of Luspatercept on
Serum Ferritin in Patients (Pts) With Lower-Risk Myelodysplastic
Syndromes (MDS) With Ring Sideroblasts (RS) in the Phase 3 MEDALIST
Trial - Abstract: e-Poster 807
Title:
Longer-Term RBC Transfusion
Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients
(Pts) With Lower-Risk myelodysplastic syndromes (MDS) with Ring
Sideroblasts (RS) - Abstract: e-Poster 813
Title:
Clinical Benefit of
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
(LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST
Study - Abstract: e-Poster 798
All e-Poster and oral abstract presentations will be made
available on the on-demand EHA25 Virtual Congress Platform
beginning on June 12, 2020 at 8:30 a.m. CEST.
About REBLOZYL® (luspatercept-aamt)
REBLOZYL is the first and only U.S. Food and Drug
Administration-approved erythroid maturation agent designed to
promote red blood cell production through a novel mechanism.
Luspatercept-aamt is being developed to treat anemia in patients
with beta-thalassemia, MDS, and myelofibrosis. REBLOZYL is part of
the global collaboration between Acceleron and Bristol Myers
Squibb.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its commercialization, research, and
development efforts in hematologic and pulmonary diseases. In
hematology, Acceleron and its global collaboration partner, Bristol
Myers Squibb, are co-promoting REBLOZYL® (luspatercept-aamt), the
first and only approved erythroid maturation agent, in the United
States for the treatment of anemia in certain blood disorders. The
Companies are also developing luspatercept for the treatment of
anemia in patient populations of MDS, beta-thalassemia, and
myelofibrosis. In pulmonary, Acceleron is developing sotatercept
for the treatment of pulmonary arterial hypertension, having
recently reported positive topline results of the Phase 2 PULSAR
trial.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on social media: @AcceleronPharma and
LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements about
Acceleron’s strategy, future plans and prospects, including
statements regarding the development and commercialization of
Acceleron’s compounds, the timeline for clinical development and
regulatory approval of Acceleron’s compounds, the expected timing
for reporting of data from ongoing clinical trials, and the
potential of Reblozyl® (luspatercept-aamt) as a therapeutic drug.
The words "anticipate," "believe," "could," "estimate," "expect,"
"goal," "intend," "may," "plan," "potential," "project," "should,"
"target," "will," "would," and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Actual results could differ materially from those included in
the forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to, that the results of
any clinical trials may not be predictive of the results or success
of other clinical trials, that regulatory approval of Acceleron’s
compounds in one indication or country may not be predictive of
approval in another indication or country, that the development of
Acceleron’s compounds will take longer and/or cost more than
planned or accelerate faster than currently expected, that
Acceleron or its collaboration partner, Bristol Myers Squibb
Corporation (“BMS”), will be unable to successfully complete the
clinical development of Acceleron’s compounds, that Acceleron or
BMS may be delayed in initiating, enrolling or completing any
clinical trials, and that Acceleron’s compounds will not receive
regulatory approval or become commercially successful products.
These and other risks and uncertainties are identified under the
heading “Risk Factors” included in Acceleron’s most recent Annual
Report on Form 10-K, Quarterly Report on Form 10-Q, and other
filings that Acceleron has made and may make with the SEC in the
future.
The forward-looking statements contained in this press release
are based on management's current views, plans, estimates,
assumptions, and projections with respect to future events, and
Acceleron does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200520005073/en/
Acceleron Pharma Inc.
Investors: Jamie Bernard, IRC, 617-649-9650 Associate Director,
Investor Relations
Media: Matt Fearer, 617-301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024